According to the US Renal Data System,
|
|
- Sylvia Glenn
- 5 years ago
- Views:
Transcription
1 DIABETIC NEPHROPATHY * Mohamed G. Atta, MD ABSTRACT *Based on a presentation given by Dr Atta at a CME dinner symposium for family physicians. Assistant Professor of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Address correspondence to: Mohamed G. Atta, MD, Johns Hopkins University School of Medicine, 18 Building, Suite 416 Renal, 6 N. Wolfe St, Baltimore, MD matta1@jhmi.edu. The prevalence of diabetes-related end-stage renal disease has increased considerably in recent years and is expected to continue to increase over the next decade. Approximately to 4 of persons with type 1 diabetes develop nephropathy. In type 2 diabetes the likelihood of progression to nephropathy varies considerably among different ethnic groups. Microalbuminuria is a significant predictor of subsequent nephropathy in patients with either type 1 or type 2 diabetes, and also predicts increased risk of a number of cardiovascular disease outcomes, including mortality. Recent evidence suggests that microalbuminuria reflects a generalized vascular disease process that is associated with increased development of atherosclerosis and impairment of endothelium-dependent blood flow regulation in clinically healthy patients. Guidelines developed by the American Kidney Foundation recommend annual screening for microalbuminuria beginning at the time of diagnosis in patients with type 2 diabetes, and 5 years after diagnosis in patients with type 1 diabetes. Microalbuminuria can regress spontaneously in many cases; factors that are associated with an increased likelihood of microalbuminuria regression include younger age and lower levels of cholesterol, triglycerides, glycosylated hemoglobin A 1c (HbA 1c ), and systolic blood pressure. First-line treatment strategies for microalbuminuria include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta blockers. The progressive course of nephropathy in patients with diabetes is not inevitable, and more intensive therapy intended to correct multiple risk factors simultaneously can produce a greater reduction in the risk of nephropathy progression than conventional treatment strategies. However, even with intensive treatment, few patients are able to reduce their HbA 1c values below 6.5. (Adv Stud Med. 5;5(4A):S276-S281) According to the US Renal Data System, the incidence of end-stage renal disease (ESRD) associated with diabetes increased markedly during the 199s, a period when the incidence of ESRD associated with hypertension, glomerulonephritis, and cystic kidney all remained relatively constant. 1 Data from the Renal Data System also suggest that approximately 5 of all patients who are on dialysis have a primary diagnosis of diabetes (mostly type 2 diabetes). By comparison, 27 of dialysis patients have hypertension, 13 have glomerulonephritis, and of patients have other causes. 1 The number of persons with ESRD as a result of diabetes is likely to continue to increase for some years to come; the World Health Organization has projected a 46 increase in the worldwide prevalence of diabetes between and, an increase from a global population of 151 million to 221 million people with diabetes. 2 It is estimated that to 4 of patients with type 1 diabetes eventually develop nephropathy. Among S276 Vol. 5 (4A) April 5
2 patients with type 2 diabetes, the prevalence of diabetic nephropathy varies from approximately 5 to in white patients, to in black patients, to as many as 6 of members in the Pima Indian tribe. 3,4 The progression of diabetic nephropathy among patients with type 1 diabetes is typically very predictable. The glomerular filtration rate (GFR) increases during the first few years of hyperglycemia as a result of hyperfiltration that is associated with microalbuminuria. After approximately years of hyperglycemia, the GFR begins to decrease, and proteinuria develops. Azotemia appears after 15 to years, followed by ESRD after to 25 years. Thus, microalbuminuria is the first manifestation of a long progressive course of gradually worsening kidney function. In general, type 2 diabetes follows this same general course. Data from clinical trials conducted over the last 2 decades suggest that this progressive course of renal dysfunction is not inevitable, and that therapeutic approaches that target a number of modifiable risk factors can slow the progression of nephropathy in patients with diabetes. ( mm Hg; P =.1). In contrast, patients who did not develop microalbuminuria exhibited a slight decrease in mean systolic blood pressure during sleep ( mm Hg; not statistically significant). Patients who exhibited a typical nocturnal decline in blood pressure (defined in this study as a ratio of systolic blood pressure during sleep to systolic blood pressure while awake of.9 or less) had a 7 lower risk of developing microalbuminuria than patients who did not exhibit this normal blood pressure pattern (Figure 1). These findings suggest that nocturnal hypertension may be an early clinical manifestation of the progression of diabetic nephropathy. The link between proteinuria and structural abnormalities of the kidney was first established by Dr Richard Bright ( ), the personal physician to Queen Victoria of England. 6 Bright was also among the first to suspect that the kidneys are important in the development of hypertension. The concept of microalbuminuria was introduced more than 4 years ago when an immunoassay method was first developed MICROALBUMINURIA AND VASCULAR DISEASE The results of a recent study suggest that abnormally elevated blood pressure during sleep may be a significant cause of microalbuminuria in patients with type 1 diabetes. 5 The investigators monitored 75 adolescents and young adults with type 1 diabetes who had normal blood pressures and albumin excretion at baseline over a 5-year period. Blood pressure was measured at baseline and then again 2 years after enrollment in the study using 24-hour ambulatory blood pressure monitoring. In normal individuals, blood pressure decreases during the course of a night s sleep and increases again upon awakening in the morning. In this study, the investigators found the patients who developed microalbuminuria exhibited an increase, rather than a decrease, in mean systolic blood pressure during sleep Figure 1. Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes Patients with type 1 diabetes who exhibit a normal nocturnal pattern of blood pressure, characterized by a decrease in blood pressure during sleep and an increase upon awakening, were less likely to progress to microalbuminuria than patients who exhibited an abnormal nocturnal pattern of increased blood pressure during sleep. Reprinted with permission from Lurbe et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2;347(11): Advanced Studies in Medicine S277
3 that made it possible to detect albumin in the urine at concentrations lower than could be detected by dipstick. 7 However, it was not until the mid-198s that researchers became interested in microalbuminuria as a predictor for diabetic nephropathy. The relationship between microalbuminuria and nephropathy was first demonstrated in patients with type 1 diabetes and was later extended to patients with type 2 diabetes. In addition, it was subsequently shown that microalbuminuria (urine albumin concentration of -14 µg/l) is actually a very strong predictor of increased cardiovascular mortality. In one study that compared cardiovascular disease outcomes between patients with diabetes and microalbuminuria and normal control subjects, mortality over a 9-year period was increased by 148 in patients with microalbumin concentrations of to 14 µg/l, by 76 in patients with microalbumin concentrations of 16 to 29 µg/l, and by 37 in patients with microalbumin concentrations below 16 µg/l. 8 The association between microalbuminuria and clinical outcomes was also demonstrated in the Heart Outcomes Prevention and Evaluation (HOPE) clinical trial, which evaluated the effects of angiotensin-converting enzyme (ACE) inhibitor therapy and several important cardiovascular risk factors on the incidence of myocardial infarction, stroke, or death from cardiovascular causes in patients with or without diabetes. 9 More than 9 patients who were at high risk of vascular events at baseline (age 55 years, evidence of vascular disease or diabetes, and at least one other cardiovascular risk factor) were randomized to treatment with either ramipril or placebo for 5 years. Microalbuminuria was actually the strongest independent predictor of cardiovascular events in this study, and was associated with a greater increase in the risk of an endpoint event than coronary artery disease or diabetes. Similarly, Borch-Johnsen and colleagues compared microalbuminuria with other traditional risk factors for ischemic heart disease in 85 patients who did not have heart disease, renal disease, urinary tract infection, or diabetes at baseline (Figure 2). After adjusting for other cardiovascular risk factors, the relative risk of ischemic heart disease among patients with microalbuminuria (defined as the group of patients who were in the upper for the urinary albumin/creatinine ratio) was 2.3 (95 confidence interval, ; P =.2). The likelihood of survival over a -year period was 97 for patients without microalbuminuria and 91 for patients with microalbuminuria (P <.1). Urinary protein excretion also predicts other forms of atherosclerotic disease. This relationship was demonstrated in a study of more than patients with or without diabetes who were evaluated over a 7- year period. 11 Whether patients had diabetes or not, the incidence of coronary heart disease, stroke, amputation, and any atherosclerotic disease event was related to increasing urinary protein concentration (Figure 3). In patients with type 2 diabetes, the incidence of stroke was 7.2 in patients without proteinuria (urinary protein <15 mg/l), 11 in patients with borderline proteinuria (urinary protein 15- mg/l), and 23 in patients with clinical proteinuria (urinary protein > mg/l; for trend). As with hypertension, it has been hypothesized that the clinical consequences of microalbuminuria are related to physical injury to the vascular endothelium of the kidney or other organs. Endothelial injury produces an increase in angiotensin II, which raises singlenephron GFR and promotes the extravasation of Figure 2. Microalbuminuria Compared with Traditional Risk Factors for Ischemic Heart Disease Adjusted Relative Risk Smoking 2.3 Microalbuminuria N = 85; -year follow-up 2.1 Male Gender 1.6 Total Cholesterol 1.2 Systolic BP The impact of microalbuminuria and other traditional risk factors on the risk for ischemic heart disease among patients free from heart disease, renal disease, urinary tract infection, or diabetes at baseline. Data from Borch-Johnsen et al. S278 Vol. 5 (4A) April 5
4 albumin (and other substances, such as oxidized lowdensity lipoprotein) into Bowman s capsule. By analyzing the albumin content of urine, it is relatively easy to measure albumin extravasation in the kidneys. A similar process of albumin extravasation may also occur at other vascular sites throughout the body, although it is more difficult to measure albumin extravasation in other tissues. In one study, the extent of systemic transvascular albumin leakage was estimated in patients with severe atherosclerosis and in healthy control subjects by examining the disappearance of radioactively labeled albumin from the vascular compartment over a 1-hour period. 12 Patients with atherosclerosis exhibited a significant increase in transvascular albumin leakage that was significantly correlated with albumin excretion in the urine. Transvascular albumin leakage has also been described in subjects who are clinically healthy but with elevated urinary albumin excretion (urinary albumin excretion rate µg per minute). 13 In addition, microalbuminuria is also associated with impaired flow-associated, endothelium-dependent dilatation of the brachial artery in clinically healthy individuals with microalbuminuria. 14 These findings suggest that microalbuminuria actually reflects a generalized vascular disease state that may promote the development of atherosclerosis by increasing the deposition of lipid in the blood vessel wall, and thereby increasing the risk of a number of different manifestations of vascular disease. SCREENING AND TREATMENT Guidelines for microalbuminuria screening of patients with diabetes have been developed by the National Kidney Foundation. 15 These guidelines recommend that a standard urinalysis be performed 5 years after diagnosis in patients with type 1 diabetes and at the time of diagnosis in patients with type 2 diabetes, and then be repeated at yearly intervals thereafter. If the urine test is positive, proteinuria should be quantified using 24-hour urine or the protein/creatinine ratio. If the standard urinalysis is negative, a nontimed screen for microalbuminuria should be performed. It is not necessary to test for microalbuminuria if standard dipstick testing is positive. Recent evidence suggests that albuminuria may be a modifiable risk factor. There is good evidence to suggest that albuminuria can be modified in patients with renal disease. There are fewer data regarding the modification of albuminuria in patients with cardiovascular or atherosclerotic disease. In many cases, microalbuminuria regresses spontaneously. The incidence of significant regression of microalbuminuria was recently examined in 386 patients with type 1 diabetes who had significant persistent proteinuria during an initial 2-year evaluation period. 16 Over 6 years of evaluation, the cumulative incidence of microalbuminuria regression (defined as a reduction in urinary albumin concentration of at least 5 from one 2- year period to the next) was 58. Several independent factors were associated with an increased likelihood of microalbuminuria regression. These include age 26 Figure 3. Incidence of CHD Events, Stroke, Lower-Extremity Amputation, and All ASVD Events in and NIDD Subjects by Urinary Protein P =.2 CHD Amputation P = Stroke ASVD U-protein <15 mg U-protein <15 mg U-protein < mg CHD = coronary heart disease; ASVD = atherosclerotic vascular disease; NIDD = non insulin-dependent diabetes. Reprinted with permission from Miettinen et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27(11): Advanced Studies in Medicine S279
5 years or younger, cholesterol level under 198 mg/dl, triglycerides under 145 mg/dl, glycosylated hemoglobin A 1c (HbA 1c ) under 8, and systolic blood pressure under 115 mm Hg. In patients with 3 of these beneficial factors, the incidence of microalbuminuria regression over 6 years was 3 times the rate of regression among patients with no beneficial factors. TREATMENT OF MICROALBUMINURIA First-line treatment strategies for microalbuminuria include ACE inhibitors, angiotensin receptor blockers (ARBs), and beta blockers. An important goal of treatment should be intensive blood pressure control. Other effective strategies include strict glycemic control, a low protein diet, statins, and aspirin. The benefit of ACE inhibitor therapy on the progression of chronic kidney disease was first demonstrated by Lewis and colleagues in patients with type 1 diabetes, urinary protein excretion of 5 mg or more per day, and serum creatinine 2.5 mg/dl or less. 17 Treatment with captopril produced a 48 reduction in the percentage of patients who doubled their serum creatinine (the study primary endpoint) over 4 years of treatment. Captopril appeared to produce a beneficial effect on renal function that was independent of its effect on blood pressure. In patients with type 2 diabetes, the Reduction of End Points in with Angiotensin II Receptor Antagonist Losartan (RENAAL) study examined the effects of angiotensin receptor blockade on the progression of renal disease. 18 Patients with type 2 diabetes and nephropathy at baseline were randomized to double-blind treatment with losartan or placebo, in combination with conventional antihypertensive treatment (calcium-channel blockers, diuretics, alpha blockers, beta blockers, and centrally acting agents) for a mean of 3.4 years. The primary endpoint was the combined incidence of the doubling of serum creatinine from baseline, ESRD, or death. Compared with placebo, treatment with the ARB losartan was associated with a 16 relative reduction in the incidence of the composite primary endpoint (P =.2) and a 28 reduction in the risk of ESRD (P =.2). In another study of patients with type 2 diabetes, a direct comparison of the ACE inhibitor captopril and the beta blocker atenolol found no significant differences between the 2 treatments in the progression to microalbuminuria (31 vs 26 for the captopril and atenolol groups, respectively) or in the progression to overt proteinuria (5 vs ) over 9 years of treatment. 19 Some data suggest that the most effective way to reduce the microvascular complications of diabetes is by combining treatments to address several risk factors simultaneously. A recent study in Denmark compared the effectiveness of an intensified treatment strategy intended to reduce several modifiable risk factors versus conventional therapy in patients with type 2 diabetes and nephropathy. Patients in the intensive therapy group were significantly more likely to attain serum cholesterol of less than 175 mg/dl and systolic blood pressure under 15 mm Hg (P.1). They also tended to have better rates of attaining HbA 1c values under 6.5, triglycerides under 15 mg/dl, and diastolic blood pressure under 8 mm Hg, although these differences were not statistically significant. Patients randomized to the intensive treatment had significantly lower rates of nephropathy (relative risk,.39; P =.3); retinopathy (relative risk,.42; P =.2); and autonomic neuropathy (relative risk,.37; P =.2). The primary endpoint, the combined incidence of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation, was reduced by approximately 5 in the intensive therapy group compared with conventional therapy. Although these findings demonstrate that aggressive intervention to modify risk factors can improve the microvascular and macrovascular complications of diabetes more than conventional treatment, it should be noted that even with the intensive treatment used in this study, fewer than of patients were able to attain HbA 1c values below 6.5. Although risk factor modification is clearly important in patients with diabetes, management of hypertension is of particular importance in preventing renal disease. It has been estimated that approximately 11 million Americans have both hypertension and diabetes. The National Kidney Foundation recommends a target blood pressure of less than 125/75 mm Hg 15 ; the American Diabetes Association recommends a target blood pressure of less than 1/8 mm Hg. 21 In patients with hypertension and type 2 diabetes with microalbuminuria and renal insufficiency (serum creatinine >1.5 mg/dl), ARBs delay the progression of nephropathy. Despite the effectiveness of antihypertensive therapy for preventing diabetes complications, many physicians are not using these medications as effectively as they could. A survey of US physicians for S28 Vol. 5 (4A) April 5
6 their prescribing habits for antihypertensive medications found that only 2 to 3 of primary care physicians reported that they start treatment for their patients with diabetes when the diastolic blood pressure is between 8 and 84 mm Hg; more than half of physicians reported that they would wait until the diastolic blood pressure is 9 to 94 mm Hg; and 3 said that they would wait until diastolic blood pressure was above mm Hg before starting treatment. 22 SUMMARY AND CONCLUSIONS The clinical course of diabetic nephropathy is typically characterized by a gradual decline in renal function that eventually culminates in ESRD. However, this clinical course is not inevitable. By controlling hyperglycemia it is possible to change the course of diabetic nephropathy; and by targeting many risk factors simultaneously, the progression of renal disease can be slowed in many patients. Considerable evidence now suggests that microalbuminuria is not simply a predictor of diabetic nephropathy, but is rather a marker for more generalized endothelial damage. Once diabetic nephropathy has been identified, management should focus on correcting several risk factors for progression. These should include lifestyle modification, tight control of blood glucose, cholesterol, and blood pressure, with the addition of medication to inhibit the renin-angiotensin system. REFERENCES 1. United States Renal Data System. Available at: 2. World Health Organization. Diabetes. Available at: /diabetes/en/. Accessed December, US Renal Data System. USRDS 2 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, Md: NIH, NIDDK;3. 4. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparitis in incidence of diabetic endstage renal disease according to race and type of diabetes. N Engl J Med. 1989;321(16): Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2;347(11): Bright R. Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine. London Med Gazette. 1835;18( ): Keen H, Chlouveraks C. An immunoassay method for urinary albumin at low concentrations. Lancet. 1963; 186: Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;3(6): Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. ;342(3): Errata in: N Engl J Med. ;342(18):1376; N Engl J Med. ; 342():748.. Borch-Johnsen K, Feldt-Rasmussen B, Standgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999;19(8): Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulindependent diabetic subjects. Stroke. 1996;27(11): Jensen JS. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15(9): Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Lond). 1995;88(6): Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt- Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 1;3(14): National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2;39(2, suppl 1):S1-S Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 3;348(23): Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329: Erratum in: N Engl J Med. 1993;3(2): Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 1;345(12): UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(716): Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 3;348(5): Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH; American Diabetes Association. Diabetic nephropathy. Diabetes Care. 3;26(suppl 1):S94-S Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. ;16(15): Advanced Studies in Medicine S281
7 NOTES S282 Vol. 5 (4A) April 5
Renal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationDiabetes has become the most common
P O S I T I O N S T A T E M E N T Diabetic Nephropathy AMERICAN DIABETES ASSOCIATION Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationDiabetes has become the most common
P O S I T I O N S T A T E M E N T Diabetic Nephropathy AMERICAN DIABETES ASSOCIATION Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due
More informationThe interest in microalbuminuria originated. Cardiovascular Implications of Albuminuria. R e v i e w P a p e r.
R e v i e w P a p e r Cardiovascular Implications of Albuminuria Katherine R. Tuttle, MD Microalbuminuria is a major independent risk factor for cardiovascular disease (CVD) events in persons with diabetes
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationAnalysis of Factors Causing Hyperkalemia
ORIGINAL ARTICLE Analysis of Factors Causing Hyperkalemia Kenmei Takaichi 1, Fumi Takemoto 1, Yoshifumi Ubara 1 and Yasumichi Mori 2 Abstract Objective Patients with impaired renal function or diabetes
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationComparison between the efficacy of double blockade and single blockade of RAAS in diabetic kidney disease
International Journal of Advances in Medicine Gupta A et al. Int J Adv Med. 2018 Aug;5(4):931-935 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183122
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationEducational and behavioral interventions hitherto published
Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study Rita Rachmani, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira,
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationIncreased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects
ORIGINAL ARTICLE Increased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects Shu Meguro, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita
More informationDevelopment of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study
J Am Soc Nephrol 14: 641 647, 2003 Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study JOHANNES F. E. MANN, HERTZEL C. GERSTEIN, QI-LONG YI, EVA M.
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationDiabetic Nephropathy
Diabetic Nephropathy Outline Introduction of diabetic nephropathy Manifestations of diabetic nephropathy Staging of diabetic nephropathy Microalbuminuria Diagnosis of diabetic nephropathy Treatment of
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationManagement of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationKidney Disease. Chronic kidney disease (CKD) requiring dialysis. The F.P. s Role in the Management of Chronic. Stages
Focus on CME at McMaster University The F.P. s Role in the Management of Chronic Kidney Disease By David N. Churchill, MD, FRCPC, FACP Presented at McMaster University CME Half-Day in Nephrology for Family
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More informationRATIONALE. chapter 4 & 2012 KDIGO
http://www.kidney-international.org chapter 4 & 2012 KDIGO Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus Kidney International Supplements (2012) 2, 363 369; doi:10.1038/kisup.2012.54
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationDiabetic retinopathy (DR) was first PROCEEDINGS DIABETIC RETINOPATHY * Ronald Klein, MD, MPH ABSTRACT
DIABETIC RETINOPATHY * Ronald Klein, MD, MPH ABSTRACT Diabetic retinopathy (DR) is characterized by the development of retinal microaneurysms, hemorrhages, deposits of leaked lipoproteins (hard exudates),
More informationROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA
ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA Type I IDDM is characterized by The abrupt onset of symptoms Insulinopenia
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationChronic kidney disease-what can you do and when to refer?
Chronic kidney disease-what can you do and when to refer? Dr Goh Heong Keong www.passpaces.com/kidney.htm Outline of Lecture Introduction Epidemiology of CKD in Malaysia/ World Complications of CKD What
More informationKDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationHypertension is a major risk factor for
OPTIMAL RISK MANAGEMENT OF THE HYPERTENSIVE PATIENT WITH MULTIPLE RISK FACTORS * Keith C. Ferdinand, MD, FACC ABSTRACT To determine the risk of cardiovascular disease in patients with hypertension, it
More informationKDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationRisk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study
Indian J Med Res 136, July 2012, pp 46-53 Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study Vijay Viswanathan, Priyanka Tilak
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationDiabetes is the most common cause of end-stage renal
Pharmacoeconomic Challenges in the Management of Diabetic Nephropathy ROGER A. RODBY, MD ABSTRACT BACKGROUND: Diabetes is the most common cause of end-stage renal disease (ESRD) kidney failure to the point
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationABSTRACT CARDIOVASCULAR RISK MANAGEMENT
Management of Hypertension in Patients with Type 2 Diabetes Saman Nazarian, MD, and Roger S. Blumenthal, MD, FACC, FCCP ABSTRACT Type 2 diabetes is a common condition that accounts for significant morbidity
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationINTRODUCTION. In this study we examined the
GLYCEMIC CONTROL PREDICTS DIABETIC EXTRARENAL MICROVASCULAR COMPLICATIONS BUT NOT RENAL SURVIVAL IN PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE Background: Control of blood pressure (BP) and
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationDiabetologia 9 Springer-Verlag 1991
Diabetologia (1991) 34:590-594 0012186X91001685 Diabetologia 9 Springer-Verlag 1991 Risk factors for macrovascular disease in mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationDiabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011
Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011 DKD: Challenging dogmas Old Dogmas Type 1 and Type 2 DN have the same natural history Microalbuminuria is an early stage of DN Tight Glycemia
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More information